246 related articles for article (PubMed ID: 23712122)
21. Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS.
Peng Ho S; Livanov V; Zhang W; Li J; Lesher T
Brain Res Mol Brain Res; 1998 Nov; 62(1):1-11. PubMed ID: 9795101
[TBL] [Abstract][Full Text] [Related]
22. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
Paton DM
Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
[TBL] [Abstract][Full Text] [Related]
23. Save Your Maximum Tolerated Dose: How to Diagnose Procedure-Related Spinal Cord Lesions After Lumbar Intrathecal Bolus Administration of Oligonucleotides in Cynomolgus Monkeys.
Korte S; Luft J; von Keutz A; Runge F; Mecklenburg L; Wozniak MM; Zander S; Ludwig FT; Pajaziti B; Romeike A; Korytko P
Int J Toxicol; 2020; 39(6):510-517. PubMed ID: 32856507
[TBL] [Abstract][Full Text] [Related]
24. Systemic and ICV Injections of Antisense Oligos into SMA Mice and Evaluation.
Aslesh T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():455-465. PubMed ID: 30171559
[TBL] [Abstract][Full Text] [Related]
25. Reducing gene expression in the brain via antisense methods.
Ouagazzal AM; Tepper JM; Creese I
Curr Protoc Neurosci; 2001 May; Chapter 5():Unit 5.4. PubMed ID: 18428503
[TBL] [Abstract][Full Text] [Related]
26. Phospholamban Inhibition by a Single Dose of Locked Nucleic Acid Antisense Oligonucleotide Improves Cardiac Contractility in Pressure Overload-Induced Systolic Dysfunction in Mice.
Morihara H; Yamamoto T; Oiwa H; Tonegawa K; Tsuchiyama D; Kawakatsu I; Obana M; Maeda M; Mohri T; Obika S; Fujio Y; Nakayama H
J Cardiovasc Pharmacol Ther; 2017 May; 22(3):273-282. PubMed ID: 27811197
[TBL] [Abstract][Full Text] [Related]
27. Targeting Ligands Deliver Model Drug Cargo into the Central Nervous System along Autonomic Neurons.
Sellers DL; Tan JY; Pineda JMB; Peeler DJ; Porubsky VL; Olden BR; Salipante SJ; Pun SH
ACS Nano; 2019 Oct; 13(10):10961-10971. PubMed ID: 31589023
[TBL] [Abstract][Full Text] [Related]
28. Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study.
Oberrauch S; Lu J; Cornthwaite-Duncan L; Hussein M; Li J; Rao G; Velkov T
J Vis Exp; 2022 Mar; (181):. PubMed ID: 35435913
[TBL] [Abstract][Full Text] [Related]
29. Targeting choroid plexus epithelia and ventricular ependyma for drug delivery to the central nervous system.
Gonzalez AM; Leadbeater WE; Burg M; Sims K; Terasaki T; Johanson CE; Stopa EG; Eliceiri BP; Baird A
BMC Neurosci; 2011 Jan; 12():4. PubMed ID: 21214926
[TBL] [Abstract][Full Text] [Related]
30. Efficient in vivo delivery of antisense oligonucleotide to choroid plexus.
Piao W; Nishina K; Yoshida-Tanaka K; Kuwahara H; Nishina T; Sakata M; Mizusawa H; Yokota T
J Med Dent Sci; 2013 Mar; 60(1):9-16. PubMed ID: 23917958
[TBL] [Abstract][Full Text] [Related]
31. Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models.
Kim Y; Jo M; Schmidt J; Luo X; Prakash TP; Zhou T; Klein S; Xiao X; Post N; Yin Z; MacLeod AR
Mol Ther; 2019 Sep; 27(9):1547-1557. PubMed ID: 31303442
[TBL] [Abstract][Full Text] [Related]
32. Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases.
Schoch KM; Miller TM
Neuron; 2017 Jun; 94(6):1056-1070. PubMed ID: 28641106
[TBL] [Abstract][Full Text] [Related]
33. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
[TBL] [Abstract][Full Text] [Related]
34. Toxicity and biodistribution of the radioprotectors, WR2721, WR77913, and WR3689, in the CNS following intraventricular or intracisternal administration.
Spence AM; Edmondson SW; Krohn KA; Grunbaum Z; Rasey JS; Steele JE
Int J Radiat Oncol Biol Phys; 1986 Sep; 12(9):1653-60. PubMed ID: 3019970
[TBL] [Abstract][Full Text] [Related]
35. Systemic Brain Delivery of Antisense Oligonucleotides across the Blood-Brain Barrier with a Glucose-Coated Polymeric Nanocarrier.
Min HS; Kim HJ; Naito M; Ogura S; Toh K; Hayashi K; Kim BS; Fukushima S; Anraku Y; Miyata K; Kataoka K
Angew Chem Int Ed Engl; 2020 May; 59(21):8173-8180. PubMed ID: 31995252
[TBL] [Abstract][Full Text] [Related]
36. Neuronal progenitor-like cells expressing polysialylated neural cell adhesion molecule are present on the ventricular surface of the adult rat brain and spinal cord.
Alonso G
J Comp Neurol; 1999 Nov; 414(2):149-66. PubMed ID: 10516589
[TBL] [Abstract][Full Text] [Related]
37. Intrathecal Delivery of Therapeutic Oligonucleotides for Potent Modulation of Gene Expression in the Central Nervous System.
Kennedy Z; Gilbert JW; Godinho BMDC
Methods Mol Biol; 2022; 2434():345-353. PubMed ID: 35213030
[TBL] [Abstract][Full Text] [Related]
38. Effect of supraspinal antisense oligodeoxynucleotide treatment on delta-opioid receptor mRNA levels in mice.
Lee CE; Kest B; Jenab S; Inturrisi CE
Brain Res Mol Brain Res; 1997 Aug; 48(1):17-22. PubMed ID: 9379841
[TBL] [Abstract][Full Text] [Related]
39. Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain.
Mohan A; Fitzsimmons B; Zhao HT; Jiang Y; Mazur C; Swayze EE; Kordasiewicz HB
Pain; 2018 Jan; 159(1):139-149. PubMed ID: 28976422
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
